Unigene has spent the last 20 years focusing on research, manufacturing and delivery technologies for peptides used for medical purposes. That unwavering focus has uniquely positioned Unigene as the only biopharma company that manufactures peptides by recombinant techniques, while also having oral and nasal delivery systems to successfully administer the peptides.
Top-tier partnerships and a portfolio of patents validate UGNE's technology platforms - Both of Unigene's technology platforms can be applied to products addressing a large variety of diseases. The Company has been awarded multiple patents to validate its technologies. Further validation for Unigene's products and technologies comes from partnerships with some top-tier names in the pharmaceutical industry. Partnerships are in place with Upsher- Smith Laboratories, Novartis Pharma AG, and GlaxoSmithKline, and collaborations are in place with world-renowned universities including University of London and Yale University Medical School.
Fortical(R), UGNE's first U.S. product, is in near-dominant position of its market - Fortical(R), Unigene's nasal calcitonin product that was launched in 2005 with partner Upsher-Smith, has exhibited substantial growth, and it currently holds 49% of the nasal sCT market estimated to be in the $200 million range. Because the market leader, Miacalcin(R) (Novartis), is approximately 50% more expensive and contains a nasal irritant (benzalkonium chloride) that is absent from Unigene's product, and because there appears to be no other near-term competitors, Fortical(R) is well positioned to continue growing sales and garnering market share to become the leader in this market.
New indication could catapult calcitonin sales to blockbuster status -
Novartis is conducting a Phase III trial investigating the effectiveness of
oral calcitonin on osteoarthritis (OA), a painful disease of the joints.
|SOURCE Unigene Laboratories Inc.|
Copyright©2008 PR Newswire.
All rights reserved